Why does a higher repseonse rate to chemotherapy correlate poorly with improved survival?
- 1 December 1993
- journal article
- editorial
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 119 (12) , 700-701
- https://doi.org/10.1007/bf01195339
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1991
- A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancerBritish Journal of Cancer, 1990
- Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.Journal of Clinical Oncology, 1990
- Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.Journal of Clinical Oncology, 1990
- Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?Cancer, 1989
- Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatmentEuropean Journal of Cancer and Clinical Oncology, 1988
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988
- Reporting results of cancer treatmentCancer, 1981